Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity
2015 · Nature Communications · 298 citations
https://doi.org/10.1038/ncomms7169
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
3
Papers
328
Citations
2
h-index
2
i10-index
Ulaganathan Baraneedharan is an academic researcher from Mitra Biotech (India). The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Cancer Cells and Metastasis & Cancer Genomics and Diagnostics. The author has an h-index of 2, co-authored 3 publications.
Click to start Chat